How to Structure Antibody-Related Transactions and Avoid Legal and Business Pitfalls
Time & Location
Aug 22, 2026, 9:00 PM – 10:00 PM EDT
Zoom
About the Event
Please register via: https://us06web.zoom.us/webinar/register/WN_9WwJ-eRVTeC8G2B2d1CEyQ
Webinar Title: How to Structure Antibody-Related Transactions and Avoid Legal and Business Pitfalls
Abstract：
The market for antibody-based transactions has become increasingly sophisticated, with assets frequently changing hands through licenses, collaborations, options, joint ventures, and M&A transactions. While commercial terms often drive deal negotiations, many of the most significant value-destroying disputes arise from issues that are addressed—or overlooked—in the transaction documents.
These risks include unclear ownership and control of intellectual property, freedom-to-operate and third-party rights, misaligned development and commercialization incentives, ambiguous field definitions and exclusivity provisions, improvement and next-generation product rights, and joint development and governance challenges.
The most successful antibody transactions are not simply those that maximize economics at signing—they are those that anticipate legal, operational, and strategic risks before they become disputes.
Speaker:
Dr. Wenseng “Wendy” Pan serves as Chair of Goodwin’s Life Sciences Practice in Asia. She focuses her practice on cross-border mergers and acquisitions, licensing transactions, strategic collaborations, and financings in the life sciences sector. Dr. Pan has advised leading global pharmaceutical companies, biotechnology companies, and investment institutions on numerous significant cross-border transactions involving a broad range of innovative therapeutic modalities, including antibody-drug conjugates, bispecific antibodies, cell therapies, and small nucleic acid therapeutics.
Dr. Pan is a graduate of Fudan University and earned both a Ph.D. in Chemistry and a J.D. from Columbia University in the United States. She is admitted to practice in the State of New York and is registered to practice before the U.S. Patent and Trademark Office. Dr. Pan has been consistently recognized by leading international legal directories, including Chambers, where she has received a Band 1 ranking, and IFLR1000. She also serves as Chair of BayHelix Group.